Skip to main content

Table 1 Clinical characteristics of patients with ICIs induced endocrine toxicity

From: Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system

 

Endocrine AEs in ICIs (6260)

Endocrine AEs in other drugs (233338)

Gender

 Male

3428(54.76)

106,643(45.70)

 Female

2095(33.47)

95,425(40.90)

 Missing

737(11.77)

31,270(13.40)

Age

  < 65

2481(39.63)

91,368(39.16)

  > =65

2496(39.87)

55,099(23.61)

 Missing

1283(20.50)

86,871(37.23)

Year

 2014

116(1.85)

17,308(7.42)

 2015

59(0.94)

37,813(16.21)

 2016

944(15.08)

47,013(20.15)

 2017

1572(25.11)

62,480(26.78)

 2018

2838 (45.34)

55,743(23.89)

 2019Q1

731(11.68)

12,981(5.56)

Outcome

 Death

601(9.60)

9752(4.18)

 Life-threatening

474(7.57)

10,435(4.47)

 Disability

108(1.73)

4958(2.12)

 Hospitalization

2329(37.20)

69,842(29.93)

 Congenital anomaly

0(0.00)

102(0.04)

 Other serious

1605(25.64)

78,742(33.75)

 Required intervention

1(0.02)

50(0.02)

 Missing

1142(18.24)

59,457(25.48)

Report countries

 United States

1997(31.90)

124,384(53.31)

 Japan

1748(27.92)

14,146(6.06)

 Great Britain

181(2.89)

11,376(4.88)

 France

393(6.28)

10,258(4.40)

 Canada

62(0.99)

8741(3.75)

 Italy

116(1.85)

7922(3.40)

 Other countries

1033(16.50)

43,567(18.67)

 Missing

730(11.66)

12,944(5.55)